Insurance Denials for Osteocel
Osteocel is a cell based substitute utilizing mesenchymal stem cell therapy. Insurance companies are denying coverage for cell based substitutes stating they are not covered due to experimental/investigational and not widely used and generally accepted for the proposed use as reported in nationally recognized peer-reviewed medical literature in the English language.
Are these denials worth appealing?
If so, what documentation are you supplying the insurance company? Are you winning?